Details of Disease

General Information of Disease (ID: DIS6FPB6)

Disease Name Ganglioneuroblastoma
Synonyms ganglioneuroblastoma (morphologic abnormality); ganglioneuroblastoma, malignant; ganglioneuroblastoma (disease); ganglioneuroblastoma
Disease Class 2A00: Brain cancer
Definition
A neuroblastic tumor characterized by the presence of neuroblastic cells, ganglion cells, and a stroma with Schwannian differentiation constituting more than fifty-percent of the tumor volume. There are two histologic subtypes identified: ganglioneuroblastoma, intermixed and ganglioneuroblastoma, nodular.
Disease Hierarchy
DISKWPS1: Neuroblastic tumor
DIS6FPB6: Ganglioneuroblastoma
ICD Code
ICD-11
ICD-11: 2A00.11
ICD-10
ICD-10: C69-C72, C71
Expand ICD-11
'XH77W7
Disease Identifiers
MONDO ID
MONDO_0005035
MESH ID
D018305
UMLS CUI
C0206718
MedGen ID
60218
HPO ID
HP:0006747
Orphanet ID
251877
SNOMED CT ID
1.16E+14

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CD171 specific CAR T cells expressing EGFRt DM2AHXW Phase 1 CAR T Cell Therapy [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 4 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CD58 TT5KSBY Strong Biomarker [2]
LGMN TTPTWV5 Strong Altered Expression [3]
MYCN TT9JBY5 Strong Genetic Variation [4]
RET TT4DXQT Strong Altered Expression [5]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
INSM1 OTG8RV8E moderate Altered Expression [6]
FUBP1 OT77SC9N Strong Altered Expression [7]
GALP OTW25XLK Strong Biomarker [8]
PHOX2B OT3SFR2O Strong Biomarker [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02311621) Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
2 Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens.Int J Cancer. 1991 Jun 19;48(4):502-10. doi: 10.1002/ijc.2910480405.
3 Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.Chem Biol Drug Des. 2018 Feb;91(2):534-544. doi: 10.1111/cbdd.13116. Epub 2017 Oct 31.
4 Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population.Tumour Biol. 2016 Mar;37(3):3739-47. doi: 10.1007/s13277-015-4192-6. Epub 2015 Oct 14.
5 Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo.Mol Cell Biol. 1993 Dec;13(12):7447-56. doi: 10.1128/mcb.13.12.7447-7456.1993.
6 INSM1 Expression in Peripheral Neuroblastic Tumors and Other Embryonal Neoplasms.Pediatr Dev Pathol. 2019 Oct;22(5):440-448. doi: 10.1177/1093526619843725. Epub 2019 Apr 11.
7 FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.J Exp Clin Cancer Res. 2019 Sep 11;38(1):400. doi: 10.1186/s13046-019-1414-6.
8 Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene.J Mol Neurosci. 2006;29(2):145-52. doi: 10.1385/JMN:29:2:145.
9 PHOX2B mutations and genetic predisposition to neuroblastoma.Oncogene. 2005 Apr 21;24(18):3050-3. doi: 10.1038/sj.onc.1208532.